-
Jan 9, 2025 | 
jrheum.org | Vivian Bykerk |Paul Emery |Roy Fleischmann
Association between abatacept exposure levels and infection occurrence in patients with rheumatoid arthritis: post hoc analysis of the AVERT-2 study Paul Emery, Roy Fleischmann, Robert Wong, Karissa Lozenski, Yoshiya Tanaka, Vivian P. Bykerk, Clifton O. Bingham, Thomas W.J. Huizinga, Gustavo Citera, Vidya Perera, Bindu Murthy, Kelly Fellows Maxwell, Julie Passarell, William D Hedrich, Daphne Williams The Journal of Rheumatology Jan 2025, jrheum.2024-0498; DOI: 10.3899/jrheum.2024-0498
-
Aug 16, 2024 | 
healio.com | Rob Volansky |Shenaz Bagha |Saakshi Khattri |Roy Fleischmann
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.
-
Mar 14, 2024 | 
acrjournals.onlinelibrary.wiley.com | Christina Charles-Schoeman |Roy Fleischmann |Eduardo Mysler |Maria Greenwald
Supporting Information Filename Description art42846-sup-0001-Disclosureform.pdfPDF document, 774.5 KB Disclosure Form art42846-sup-0002-Supinfo.pdfPDF document, 2.3 MB Supporting Information S1
-
Nov 10, 2023 | 
ard.bmj.com | Roy Fleischmann |Vibeke Strand |Tatsuya Atsumi |Iain B McInnes
AbstractObjectives To investigate the efficacy and safety of otilimab, an antigranulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis. Methods Two phase 3, double-blind randomised controlled trials including patients with inadequate responses to methotrexate (contRAst 1) or conventional synthetic/biologic disease-modifying antirheumatic drugs (cs/bDMARDs; contRAst 2).
-
Sep 12, 2023 | 
ard.bmj.com | Roy Fleischmann |Vibeke Strand |Tatsuya Atsumi |Iain B McInnes
In contRAst 1, otilimab 90 mg resulted in a significantly greater proportion of patients achieving CDAI LDA at week 12 vs placebo, but otilimab 150 mg did not (20.9% (p=0.0188) and 19.8% (p=0.0368) vs 13.9%). In contRAst 2, both doses resulted in a significant difference versus placebo (26.5% and 25.1%, respectively, vs 11.4%, p<0.0001 for both) (figure 2, table 2, online supplemental figure 3).
-
Aug 14, 2023 | 
acrjournals.onlinelibrary.wiley.com | Roy Fleischmann
Corresponding Author Roy Fleischmann MD Clinical Professor of Medicine, Co-Medical Director University of Texas Southwestern Medical Center, Dallas, Texas Metroplex Clinical Research Center, Dallas, Texas Corresponding author: Roy Fleischmann, 8144 Walnut Hill Lane, Suite 810, Dallas, Texas 75231, USA. [email protected], 214-540-0645Search for more papers by this author
-
Aug 11, 2023 | 
ard.bmj.com | Roy Fleischmann |Jeffrey Curtis |Christina Charles-Schoeman |Eduardo Mysler
Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Jul 19, 2023 | 
onlinelibrary.wiley.com | Roy Fleischmann
Editorial This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/art.42643.
-
Jul 18, 2023 | 
pericles.pericles-prod.literatumonline.com | Roy Fleischmann
Editorial Find It @ Georgia Southern This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/art.42643. Get access to the full version of this article. View access options below.
-
Jun 12, 2023 | 
ard.bmj.com | Roy Fleischmann |Jeffrey Curtis |Christina Charles-Schoeman |Eduardo Mysler
DiscussionThe publication of the findings from ORAL Surveillance has engendered discussion regarding the safety of JAKi as a class relative to TNFi, particularly for the occurrence of MACE and malignancy but also VTE, SIE and mortality.3 Importantly, it should be noted that these AEs of special interest were also observed in patients treated with TNFi but numerically less, underscoring the need to evaluate the potential risk in all patients when prescribing any therapy for RA.
